BASF's Post-Evonik Playbook: Geismar Output, a Mining Divestment and the Margin Question
Published on 11/22/2026 at 06:01 | Editorial boerse-global.deBASF shares slipped 2.6% on Friday in a soft broader market, the day after the chemicals group walked away from its pursuit of Evonik. Rather than dwell on the failed bid, the more instructive question for investors is whether BASF can squeeze more earnings out of assets it already controls — and how convincingly it can frame that case before its capital markets day on 23 and 24 November 2026.
The abandoned takeover still shapes the backdrop. Evonik turned down two non-binding all-cash offers, the last of which BASF said stood at EUR 24 per Evonik share. BASF argued that Evonik's standalone prospects and risks did not warrant a higher valuation, and management judged that lifting the price further would conflict with the interests of its own shareholders. BNP Paribas read the retreat as an added burden on the stock.
Two very different yardsticks
What replaces the Evonik option is a pair of self-help projects that pull in opposite directions. On 11 November, BASF started up its new MDI plant at the Geismar integrated site in Louisiana, a roughly USD 1 billion investment. The company put annual capacity for the entire site at about 600,000 tonnes — a figure that covers the whole complex, not the new line alone.
A day later, BASF agreed to sell its global mining solutions business to SNF, with closing targeted for 2027 subject to regulatory clearance and customary conditions. No financial details were disclosed.
Neither announcement settles the valuation debate on its own. Commissioning a plant is an operational milestone; nameplate capacity says nothing about utilisation rates or profitability. A divestment, meanwhile, shrinks the portfolio without revealing what the retained business earns. The relevant test in both cases is whether the extra output — or the capital freed up — justifies the money committed.
Should investors sell immediately? Or is it worth buying BASF?
Jefferies and Bernstein split the difference
Sell-side opinion is sharply divided. Jefferies moved BASF to "Underperform" from "Hold" on 11 November, keeping a EUR 44 target. Analyst Priyanka Patel pointed to eroding margins, persistent overcapacity and higher gas prices, with no demand recovery in sight. Those pressures compound: when weak demand collides with surplus capacity, passing higher costs through in pricing becomes harder. Jefferies had flagged strategic merits in an Evonik deal but also risks around a European focus and synergy delivery, so a fresh approach would not automatically be read as good news.
Bernstein Research, by contrast, reaffirmed "Outperform" and a EUR 59 target on Thursday. Analyst James Hooper sees scope for further talks despite the collapse. The RAG-Stiftung, Evonik's largest shareholder, said it regretted that the two boards never reached deeper negotiations and restated its intention to reduce its Evonik stake step by step.
Agriculture adds a longer-dated lever
BASF's crop science arm offers a third data point. The company pegs peak sales potential for Nemasphere, its soybean resistance trait, at more than EUR 300 million, with varieties carrying the trait due to reach US and Brazilian growers from 2028. That is a revenue figure, not a margin figure, and the launch sits well beyond the current planning horizon.
Put the pieces together and the bull case rests on execution rather than market recovery. A profitably utilised Geismar site could underpin the value of the existing business without Evonik returning to the table or BASF raising its offer. Nemasphere could add top-line growth later in the decade. The bear case has demand staying soft while overcapacity and energy costs keep squeezing spreads — a combination in which progress on individual projects may be too small to offset pressure elsewhere.
What the capital markets day must deliver
For the November gathering, the questions that matter are specific: what demand and cost assumptions management is willing to put its name to, which improvements it believes it can achieve under its own steam, and which depend on a friendlier market. First disclosures on Geismar's utilisation or earnings contribution would be the clearest signal. Evidence of a viable profit contribution would give the standalone story a firmer footing; signs of weak returns would undercut the case for a higher multiple.
Price discipline on Evonik does not make a homegrown investment profitable by default, and a resumed dialogue would be a separate event to be judged on terms and expected benefit. Until then, Geismar is the concrete benchmark: the plant is running, and it now has to prove its worth through operations.
Ad
BASF Stock: New Analysis - 22 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
